苯达莫司汀致肾性尿崩症 1 例报告。
Bendamustine-induced nephrogenic diabetes insipidus - A case report.
机构信息
Faculty of Pharmacy, Université de Montréal, Montreal, Canada.
Division of Hematology and Oncology, Department of Medicine, Hôpital du Sacré-Cœur de Montréal, Montreal, Canada.
出版信息
J Oncol Pharm Pract. 2022 Jan;28(1):205-210. doi: 10.1177/10781552211013878. Epub 2021 May 14.
INTRODUCTION
In patients with relapsed or refractory lymphoma, high-dose chemoimmunotherapy with subsequent autologous hematopoietic cell transplantation (HCT) is a standard of care. Bendamustine, an alkylating agent, is used in the BeEAM (bendamustine, etoposide, cytarabine, melphalan) protocol for conditioning therapy before autologous HCT in patients with relapsed or refractory lymphoma who are eligible for transplant. There is no consensus regarding an optimal salvage regimen and the approach varies according to toxicity.
CASE REPORT
We present a case of partial nephrogenic diabetes insipidus after receiving bendamustine, as part of the BeEAM protocol. The patient was managed with parenteral fluid administration and intranasal desmopressin before the condition resolved on its own.
DISCUSSION
We summarize published reports of bendamustine-induced diabetes insipidus.
简介
在复发或难治性淋巴瘤患者中，高剂量化疗免疫治疗联合随后的自体造血细胞移植（HCT）是一种标准的治疗方法。苯达莫司汀是一种烷化剂，用于符合移植条件的复发或难治性淋巴瘤患者自体 HCT 前的 BeEAM（苯达莫司汀、依托泊苷、阿糖胞苷、美法仑）方案中的预处理治疗。对于最佳挽救治疗方案尚无共识，而且治疗方法因毒性而异。
病例报告
我们报告了一例在接受苯达莫司汀治疗后出现部分肾源性尿崩症的病例，该患者接受了 BeEAM 方案治疗。患者接受了静脉补液和鼻内去氨加压素治疗，之后病情自行缓解。
讨论
我们总结了已发表的关于苯达莫司汀引起的尿崩症的报告。
Zotero 插件